Navigation Links
Landauer, Inc. Reports Fiscal 2011 Third Quarter Results
Date:8/9/2011

1Summary Consolidated Balance Sheets(unaudited, amounts in thousands) June 30,September 30,20112010ASSETSCurrent Assets:Cash and cash equivalents

$
8,019$
7,659Receivables, net of allowances

25,63323,702Other current assets

11,26014,796Total current assets

44,91246,157Net property, plant and equipment

45,96139,815Equity in joint ventures

9,8148,446Goodwill and other intangible assets, net of amortization

50,83249,270Dosimetry devices, net of depreciation

5,9415,569Other assets

3,4821,439TOTAL ASSETS

$   160,942$   150,696LIABILITIES AND STOCKHOLDERS' EQUITYCurrent Liabilities:Accounts payable

$
,626$
7,180Dividends payable

5,3045,143Deferred contract revenue

16,06114,305Short-term debt

12,88412,504Other current liabilities

11,46910,420Total current liabilities

52,34449,552Non-Current Liabilities:Pension and postretirement obligations

10,46410,089Deferred income taxes

9,9879,934Other non-current liabilities

1,3191,418Total non-current liabilities

21,77021,441Stockholders' Equity:Landauer, Inc. stockholders' equity

85,66378,790Noncontrolling interest

1,165913Total stockholders' equity

86,82879,703TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY

$   160,942$   150,696Reconciliation of Net Income toEarnings before Interest, Taxes, Depreciation and Amortization(unaudited, amounts in thousands)Three Months Ended

Nine Months EndedJune 30,

June 30,2011

2010

2011

2010Net income attributed to Landauer, Inc.

$
5,536

$
,180

$   19,352

$   19,118Add back:Interest and other income

(524)

(138)

(1,667)

(1,098)Income taxes

2,667

1,791

9,698

8,806Depreciation and amortization

2,146

1,672

5,750

4,735Earnings before
'/>"/>

SOURCE Landauer, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Landauer, Inc. Sets Date and Time for Announcement of Fiscal First Quarter 2010 Results
2. Landauer, Inc. Sets Date and Time for Announcement of Fiscal Fourth Quarter and Full Year 2009 Results
3. Landauer, Inc. Declares Regular Cash Dividend
4. Landauer, Inc. Sets Date and Time for Announcement of Fiscal First Quarter 2011 Results
5. Landauer, Inc. Declares Regular Cash Dividend
6. Landauer, Inc. Sets Date and Time for Announcement of Fiscal Second Quarter 2011 Results
7. Landauer, Inc. Declares Regular Cash Dividend
8. Landauer, Inc. Sets Date and Time for Announcement of Fiscal Third Quarter 2011 Results
9. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
10. Spherix Reports Second Quarter Earnings
11. Tapestry Reports Second Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... 2013  Sorrento Therapeutics, Inc. (OTCBB: SRNE; or ... Small Business Technology Transfer Research (STTR) grant (#1R42AI098182-02) ... Diseases (NIAID), a division of the National Institutes ... human antibody therapeutics to combat Staphylococcus aureus ... including methicillin-resistant S. aureus (MRSA), was ...
(Date:5/17/2013)... CHAMPAIGN, Ill. , May 17, 2013  Sony ... new Sony SP6800 Spectral Analyzer (SP6800).  Sony will be ... 2013, which will be held at the ... San Diego, California , from May 20 - ... Sony,s second analytical system, incorporating commercial audio-visual technologies into ...
(Date:5/17/2013)... 17, 2013 /PRNewswire-iReach/ -- The escalation of new ... placing renewed emphasis on alternate delivery technologies. Alternate ... number of factors are converging to create both ... their delivery device partners . These include new ... growing trend toward self-administration for chronic diseases, shifting ...
Breaking Medicine Technology:Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases 2Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases 3Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases 4Sony Biotechnology Inc.'s New Technology for Science Provides Researchers Results in Color 2Pharmaceutical Makers and Delivery Device Partners Rethink Delivery Technologies - New Report Examines this Evolving Segment 2Pharmaceutical Makers and Delivery Device Partners Rethink Delivery Technologies - New Report Examines this Evolving Segment 3
... , July 16 Warner Chilcott ... received a communication from the U.S. Food & Drug Administration ... delayed-release tablets extending the Prescription Drug User Fee Act (PDUFA) ... additional information solicited by the FDA and previously provided by ...
... , July 15 LyoTechnica, LLC has ... drug development services for injectable pharmaceuticals. The company and ... in lyophilization and liquid dosage form development as well ... of parenteral drugs. The company offers analytical and formulation ...
Cached Medicine Technology:Warner Chilcott Announces 3-Month Extension of PDUFA Date on Next Generation Actonel Product 2Warner Chilcott Announces 3-Month Extension of PDUFA Date on Next Generation Actonel Product 3Formation of Contract Parenteral Drug Development Services Company Announced 2
(Date:5/18/2013)... Orlando, FL (May 18, 2013) A ground-breaking ... colorectal care, according to research presented today at ... optimizing the minimal withdrawal time for colonoscopies and ... , During colonoscopy, doctors use a device called ... test for colorectal cancer allows a doctor to ...
(Date:5/18/2013)... New York (PRWEB) May 18, 2013 ... pelvic mesh products continue to move forward in a ... Court, Bernstein Liebhard LLP reports. According to a notice ... in the Ethicon pelvic mesh litigation will be held ... 2,755 complaints have been filed in the proceeding on ...
(Date:5/18/2013)... HealthDay Reporter , , FRIDAY, May 17 (HealthDay News) -- ... drink, but new research shows that college women are more ... basis than are college men. Much of this ... safe on a weekly basis is much lower for women ... 14 for men. But, there,s good reason for that difference. ...
(Date:5/18/2013)... After working diligently for months and putting in ... the integration of the fitment specs for the redesigned 2012 ... stun the automobile market with its extraordinary features and unique ... as the latest entry in the size it up ... the year 2013. , Aptly suiting its name, 2012 ...
(Date:5/18/2013)... 2013 Family Magazine of Washington DC was ... Follow Media Consulting, Inc. in the category of Summer ... and dedication of the areas best in the ultimate guide ... parenting better than Brenda Hyde, a mother of four and ... know about the vast resources available to them in the ...
Breaking Medicine News(10 mins):Health News:New colonoscope provides ground-breaking view of colon 2Health News:New colonoscope provides ground-breaking view of colon 3Health News:New colonoscope provides ground-breaking view of colon 4Health News:Transvaginal Mesh Lawsuits: Bernstein Liebhard LLP Notes Upcoming Case Management Conference in New Jersey Ethicon Pelvic Mesh Litigation 2Health News:Transvaginal Mesh Lawsuits: Bernstein Liebhard LLP Notes Upcoming Case Management Conference in New Jersey Ethicon Pelvic Mesh Litigation 3Health News:College Women More Prone to Problem Drinking Than Men: Study 2Health News:College Women More Prone to Problem Drinking Than Men: Study 3Health News:Renowned Rim Fitments Provider SizeItUp Launched Database Integrations for the 2012 Hyundai Genesis 2Health News:Summer Camps in DC "Best of the Best" Awarded to Family Magazine of Washington DC for Excellence by Follow Media Consulting, Inc. 2
... suitable treatment mode for women diagnosed with breast cancer who ... should consider hormonal treatments to reduce their risk of a ... study led by researchers at the University of Michigan Comprehensive ... genetic mutation who had their ovaries removed or took the ...
... as a custom rather than as a matter of choice. ... waywardness //in the females while some clans even consider it ... initiating teenage girls into adulthood. ,As tradition goes ... which are often unsterilized. In addition the area of excision ...
... in regulating cell death, a Queen’s University study has found. ... be used to promote cell death in cancer cells but ... in neuronal cells in the case of Alzheimer’s or Parkinson’s. ... Medicine with the Cancer Biology and Genetics division of Queen’s ...
... new survey nearly 12 million Americans are affected by peripheral ... arteries are blocked that brings blood to the legs due ... is likely to increase in the coming decades and it’s ... drugs to treat it. , ,By examining the physiology ...
... sector educational group Amity Institutions have decided to launch ... plans to set up academic and training infrastructure in ... in an effort to expand the educational facilities in ... President, and board member of Ritnand Balved Education Foundation, ...
... the breast cancer in younger black women nothing significant has ... women the number of black women affected by breast cancer ... the black women is much higher when compared with the ... 50 have a 77 percent of mortality rate. ...
Cached Medicine News:Health News:Breast-Sparing Surgery: An Optional Treatment Mode For Women With Breast Cancer 2Health News:Breast-Sparing Surgery: An Optional Treatment Mode For Women With Breast Cancer 3Health News:Female Circumcision Rampant in Africa 2Health News:Protein’s role in regulating cell death sets direction for Alzheimer’s, Parkinson’s and cancer resea 2Health News:New Test to Diagnose the Peripheral Arterial Disease (PAD) 2Health News:Breast Cancer Mortality Rate is Higher Among Black Women 2Health News:Breast Cancer Mortality Rate is Higher Among Black Women 3
Ophthalmic Nd Yag Laser with excellent quality optics for clear image and good laser delivery. Compact and light-weight for portability....
The compact size and portability of the Epic system makes it a cost-effective solution for single or multi-office use....
A conventional blue visibility-tinted daily-wear lens, custom made for astigmats with up to -3.00 D of cylinder requiring adds of up to +2.50 D....
A soft contact lens that lets presbyopes see clearly and comfortably at all distances , without the hassles of bifocals or reading glasses. Recommended for daily wear. Also approved for extended wear...
Medicine Products: